Switch to Serdolect
Switch patients to the BENEFITS of Serdolect
Serdolect is a non-sedating antipsychotic drug for the treatment of schizophrenia. It reduces the risk of additional cognitive reductions in psychotic patients. This is due to its non-sedative and anti-cholinerg effect, as well as EPS on placebo-level.
Serdolect (sertindole) is a limbic-selective antipsychotic with a unique neuropharmacological profile.
Serdolect mode of action
“Sertindole is an antipsychotic drug with affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and α1-adrenoreceptors. Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a low dopamine D2 occupancy level. These features may explain the clinically observed low frequency of extrapyramidal side effects, including tardive dyskinesia. In contrast to most antipsychotics, sertindole seems to be void of sedative effects. However, although not strictly proven by objective neuropsychological tests, this asset of sertindole does not add to the cognitive problems inherent in schizophrenia” (ref. 1)